A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation

American Journal of Kidney Diseases

Volumn 27, Issue 6, 1996, Pages 855-864

  Shield III, C F ^a   Jacobs, R J ^a   Wyant, S ^a   Das, A ^a  

^a Christi Regional Medical Center   (United States)

Author keywords

cost effectiveness; induction therapy; kidney transplantation; OKT3

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; OKT 3; PREDNISONE;

ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICARE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0029896066     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(96)90524-7     Document Type: Article

References (51)

1. NG Levensky RA Rettig The Medicare End Stage Renal Disease Program, a report from the Institute of Medicine N Engl J Med 324 1991 1143 1148
2. United Network for Organ Sharing Semi-Annual Report 1991 UNOS Richmond, VA
3. RW Evans Need, demand and supply in kidney transplantation: A review of the data, an examination of the issues, and projections through the year 2000 Semin Nephrol 12 1992 234 255
4. RW Evans DL Manninen A Maier LP Garrison Jr LG Hart The quality of life of kidney and heart transplant recipients Transplant Proc 17 1985 1579 1582
5. RW Evans DL Manninen LP Garrison Jr LG Hart The quality of life of end stage renal disease patients N Engl J Med 312 1985 553 559
6. JP Johnson CR McCauly JB Copley The quality of life of hemodialysis and transplant patients Kidney Int 22 1982 286 291
7. AJ Christensen JM Holman CW Turner JR Slaughter Quality of life in end stage renal disease: Influence of renal transplantation Clin Transplant 3 1989 46 53
8. FK Port RA Wolfe EA Mauger DP Berling K Jiang Comparison of survival probabilities for dialysis patients versus cadaveric renal transplant recipients JAMA 270 1993 1339 1343
9. PV Stange AT Sumner Predicting treatment costs and life expectancy for end stage renal disease N Engl J Med 298 1978 372 378
10. H Krakauer Assessment of alternative technologies for the treatment of end stage renal disease Isr J Med Sci 22 1986 245 259
11. PW Eggers Effect of transplantation on the Medicare ESRD program N Engl J Med 318 1988 223 229
12. RW Evans Cost-effectiveness analysis of transplantation Surg Clin North Am 66 1986 603 616
13. O Salvatierra NJ Feduska F Vincenti R Duca D Potter J Nolan KC Cochrum WJC Amend Analysis of costs and outcomes of renal transplantation at one center JAMA 241 1979 1469 1473
14. P Eggers Comparison of treatment costs between dialysis and transplantation Semin Nephrol 12 1992 284 289
15. WM Bennet Basic mechanism and pathophysiology of cyclosporine nephrotoxicity Transplant Proc 17 suppl 1 1985 297 302
16. AG Dietheim Clinical diagnosis and management of the renal transplant recipient with cyclosporine nephrotoxicity Transplant Proc 18 suppl 1 1986 82 87
17. BG Sommer ML Henry RM Ferguson Sequential antilymphoblast globulin and cyclosporine for renal transplantation Transplant Proc 19 1987 1879 1880
18. G Goldstein An overview of Orthoclone OKT3 Transplant Proc 18 1986 927 930
19. GJ Beilman CF Shield JD Hughes HK Kelley LG Ward D Beck The effects of intraoperative administration of OKT3 during renal transplantation Transplantation 55 1993 490 493
20. DJ Abramowicz M Goldman L De Pauw JL Vanherweghem P Kinnaert P Vereerstraeten The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation: A single-center, prospective, randomized study Transplantation 54 1992 433 437
21. DJ Norman L Kahana FP Stuart JR Thistlethwaite CF Shield A Monaco J Dehlinger S-C Wu A Van Horn TP Haverty A randomized clinical trial of induction therapy with OKT3 in kidney transplantation Transplantation 55 1993 44 50
22. DL Nicol AS MacDonald P Belitsky S Lee AD Cohen H Bitter-Suermann J Lowen A Whalen Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary cytomegalovirus disease in renal transplant recipients Transplantation 55 1993 841 846
23. Redbook. Oradell, NJ, Medical Economics Co., 1992
24. A Ludbrook A cost-effectiveness analysis of the treatment of chronic renal failure Appl Economics 13 1981 337 350
25. RW Evans DL Manninen C Thompson A cost and outcome analysis of kidney transplantation: The implications of initial immunosuppressive protocol and diabetes 1989 Battelle Human Affairs Research Centers Seattle, WA
26. SD Roberts DR Maxwell TL Gross Cost-effective care of end-stage renal disease: A billion dollar question Ann Intern Med 92 1980 243 248
27. JM Eisenberg A guide to the economic analysis of clinical practices JAMA 262 1989 2879 2886
28. SA Finkler The distinction between cost and charges Ann Intern Med 96 1982 102 109
29. RW Evans The cost of organ transplantation: A review of the literature RW Evans DL Manninen DL Dong The National Cooperative Transplantation Study Final Report 1991 Battelle-Seattle Research Center Seattle, WA
30. RW Evans Organ transplantation costs, insurance coverage, and reimbursement P Terasaki Clinical Transplants 1990 1991 UCLA Tissue Typing Laboratory Los Angeles, CA 343 355
31. MF Drummond Allocating Resources Int J Technol Assess Health Care 6 1990 77 92
32. Current consumer price indices 1992 Bureau of Labor Statistics Washington, DC
33. RW Evans Financial aspects of organ transplantation: A summary of results from the National Cooperative Transplantation Study RW Evans DL Manninen DL Dong The National Cooperative Transplantation Study Final Report 1991 Battelle-Seattle Research Center Seattle, WA
34. MEDPAR. Washington, DC, Health Care Financing Administration, 1990
35. DL Manninen RW Evans MK Dugan B Rader The costs and outcome of kidney transplant graft failure Transplant Proc 23 1991 1312 1314
36. Physicians Fee Guide 1992 Healthcare Consultants, Inc Augusta, GA 1992
37. MA Stephens EDF Statistics for goodness of fit and some comparisons J Am Stat Assoc 69 1974 730 737
38. EL Kaplan P Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
39. N Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
40. ET Lee Statistical methods for survival analysis 1980 Lifetime Learning Publications Belmont, CA
41. MC Weinstein WB Stason Foundations of cost-effectiveness analysis for health and medical practices N Engl J Med 296 1977 716 721
42. AC Gulanikar AS MacDonald U Sungurtekin P Belitsky The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaveric kidney transplants Transplantation 53 1992 323 328
43. AJ Matas KJ Gillingham WD Payne JS Najarian The impact of an acute rejection episode on long-term renal allograft survival (t 1 2 ) Transplantation 57 1994 857 859
44. MG Hegewald JB O'Connell DG Renlund HR Lee NA Burton SV Karwande KW Jones JE Lassetter MR Bristow OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation J Heart Transplant 8 1989 303 310
45. CF Shield Antilymphocytic induction therapy in cadaver renal transplantation: The UNOS experience Presented at 13th Annual Meeting of the American Society of Transplant Physicians Chicago, IL May 16–18, 1994
46. L Alonso-Pulpon S Serrano-Fiz JA Rubio MA Cavero L Silva I Sanchez-Vegazo R Burgos CG Montero C Maicas M Kreisler Efficacy of low-dose OKT3 therapy as cytolytic induction therapy in heart transplantation J Heart Lung Transplant 14 1995 136 142
47. R Alloway M Kotb LW Gaber S Vera F Boskey AO Gaber Standard versus low OKT3 induction therapy of cadaveric renal transplantations: Comparison of outcome data versus OKT3 dose and serum levels Clin Transplant 46 1992 468 472
48. CF Shield Effect of induction immunosuppression for cadaver renal transplantation at the St. Francis Regional Medical Center P Terasaki Clinical Transplants 1990 1991 UCLA Tissue Typing Laboratory Los Angeles, CA 265 274
49. Health Care Financing Administration, Bureau of Data Management and Strategy Data from the Program Medical Information System 1985
50. LG Hunsicker EB Edwards TJ Breen OP Daily Effect of center size and patient-mix covariates on transplant center-specific patient and graft survival in the U.S. Transplant Proc 25 1993 1318 1320
51. D Anaise The non-heartbeating cadaveric donor: A solution to the organ donor crisis UNOS Update 8 1992 32 34